logo.jpg
Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.
April 21, 2023 11:55 ET | Vallon Pharmaceuticals Inc.
Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T (“NKT”) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune...
Logo.png
IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001
April 19, 2023 08:30 ET | Imunon, Inc.
Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical studies LAWRENCEVILLE, N.J., April 19, 2023 (GLOBE...
Logo.jpg
Biostage Appoints Ron Packard to Board of Directors
April 10, 2023 09:30 ET | Biostage, Inc.
HOLLISTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in...
Logo.jpg
Biostage Announces $6 Million Financing to Advance Clinical Trial
April 06, 2023 09:30 ET | Biostage, Inc.
HOLLISTON, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in...
logo.png
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
March 29, 2023 07:00 ET | BIOXYTRAN, INC.
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most symptoms by day 7 Galectin antagonist acts as an entry inhibitor for use in...
Logo.png
IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023
March 23, 2023 08:30 ET | Imunon, Inc.
LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
Logo.png
Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023
March 22, 2023 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and co-CEO, will present a company overview at the Virtual Investor Summit...
logo.png
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
February 22, 2023 08:00 ET | BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat...
logo.png
Bioxytran to Appear on ClearThink IR’s Virtual Live Event
February 14, 2023 09:00 ET | BIOXYTRAN, INC.
 - Wednesday, February 15th, 2023 12:00 EST  - Virtual Fireside Chat via Paltalk Platform BOSTON, MASSACHUSETTS, Feb. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”),...
logo.png
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
February 06, 2023 09:00 ET | BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19...